Terns Pharmaceuticals, Inc. 8-K

What Happened

• On March 24, 2026, Terns Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary (Thailand Merger Sub, Inc.). Merck will cause the Purchaser to commence a tender offer to buy all outstanding Terns common shares at $53.00 per share.
• The Purchaser’s obligation to pay for tendered shares is subject to customary conditions, including valid tenders representing a majority (one more than 50%) of outstanding shares, expiration/termination of the Hart‑Scott‑Rodino (HSR) waiting period, and no governmental order prohibiting the transaction. After the Offer is consummated, Purchaser will merge into Terns and Terns will become a wholly owned Merck subsidiary under Delaware law (Section 251(h)).
• The filing (8-K) was accompanied by a joint press release dated March 25, 2026 and states that tender offer materials (Schedule TO) and a solicitation/recommendation statement (Schedule 14D‑9) will be filed when the Offer is launched.

Key Details

• Offer Price: $53.00 per share in cash.
• Closing conditions & timeline: Offer must result in valid tenders of >50% of shares and clearances under the HSR Act; End Date is Sept 24, 2026 (automatically extendable twice to Dec 24, 2026 and Mar 24, 2027 for HSR delays).
• Equity treatment: Outstanding non‑affiliate shares accepted in the Merger convert to the $53 cash consideration; in‑the‑money options and RSUs will be cancelled for cash payments based on the $53 price; out‑of‑the‑money options will be cancelled with no consideration; certain pre-funded warrants will be cashed out via automatic cashless exercise at offer acceptance. Equity plans will be terminated at the Effective Time.
• Break fees: Terns would owe Merck a $235 million termination fee in specified circumstances (e.g., to accept a Superior Proposal); Merck would owe Terns a $270 million reverse termination fee if the deal fails due to certain antitrust restraints or HSR clearance failure by the End Date.

Why It Matters

• This 8‑K signals a proposed cash acquisition at a fixed $53 per share and starts the formal process that could result in Terns becoming a wholly owned Merck subsidiary. For stockholders, the transaction would generally convert publicly held shares and many equity awards into cash if completed.
• The Offer is subject to regulatory (HSR) approval and a majority tender condition, so completion is not guaranteed. Tender offer materials and Terns’ formal recommendation (Schedule 14D‑9) will provide the documents and guidance investors should review before deciding whether to tender shares.